Q2 2025 Earnings Call Transcript August 1, 2025 Fulgent Genetics, Inc. misses on earnings expectations. Reported EPS is $-0.62065 EPS, expectations were $-0.23. Operator: Greetings, and welcome to the ...

Fulgent Genetics Inc (FLGT) reports a 16% increase in core revenue and expands market reach, despite facing GAAP losses and ...

That was accompanied by a double-digit improvement in revenue.

Monolithic Power Systems reported quarterly earnings of $4.21 per share which beat the analyst consensus estimate of $4.11 ...

Of the 30 companies in the index, 20 firms saw their stock price decline, eight saw their share price increase, and two were flat month over month.

Fulgent Genetics (FLGT) delivered earnings and revenue surprises of +130.43% and +7.80%, respectively, for the quarter ended June 2025. Do the numbers hold clues to what lies ahead for the stock?

Fulgent Genetics ranks at the bottom for Revenue Growth and Gross Profit, with negative percentages. It is also at the bottom for Return on Equity, with a negative percentage. Overall, Fulgent ...

FulgentExome is a patient-centric, phenotype-driven analysis designed to examine coding regions and splice junctions for more than 4600 genes and to report only the variants, which are of plausible ...

FLGT Investors Have Opportunity to Join Fulgent Genetics, Inc. Fraud Investigation with the Schall Law Firm ...

Fulgent Genetics is a biotech company with a profitable COVID-19 diagnostics segment that will be negligible going forward. Read why I rate FLGT stock a Buy.

We recently compiled a list of the 10 Best Genomics Stocks To Buy Right Now. In this article, we are going to take a look at where Fulgent Genetics, Inc.